NCT04729959 2026-04-01
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT05423210 2025-12-22
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
Stony Brook University
Phase EARLY_PHASE1 Recruiting
NCT05039281 2025-12-19
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06069726 2025-10-31
MOAB
Duke University
Phase 2 Recruiting
NCT03174197 2025-09-24
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04808245 2025-09-22
INTERCEPT-H3
German Cancer Research Center
Phase 1 Active not recruiting
NCT03673787 2025-05-14
IceCAP
Institute of Cancer Research, United Kingdom
Phase 1/2 Active not recruiting
NCT04160494 2025-05-11
D2C7-IT With Atezolizumab for Recurrent Gliomas
Duke University
Phase 1 Active not recruiting
NCT06328036 2024-12-30
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT03158389 2023-09-28
N²M²
University Hospital Heidelberg
Phase 1/2 Completed
NCT03973879 2020-02-11
Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma
Duke University
Phase 1/2 Withdrawn